CD38 and Miyoshi myopathy: Another one of the strategies already used is combining the use of CD38 mAbs with IMiDs, since IMiDs are able to induce NK cell activation and CD38 upregulation on MM cells, leading to a synergistic enhancement of the cytotoxic effects of CD38 mAbs (52).